拉丁美洲多发性骨髓瘤治疗模式与临床结局:HOLA观察性研究(2008-2016)
该回顾性队列研究纳入1103例2008-2015年诊断并启动一线治疗的拉丁美洲多发性骨髓瘤患者,中位年龄61岁。一线治疗中沙利度胺方案和化疗使用下降,硼替佐米方案或硼替佐米联合沙利度胺使用上升;
要点
- 复发患者PFS较短,公立诊所新疗法采用较慢,提示治疗需求未满足
核心结论
- 拉丁美洲多发性骨髓瘤治疗模式随时间变化,硼替佐米方案使用增加而沙利度胺和化疗使用减少。
- 复发患者PFS较短,公立诊所新疗法采用较慢,存在未满足的治疗需求。
研究设计与样本
- 回顾性队列研究,纳入1103例2008-2015年诊断并启动一线治疗的拉丁美洲多发性骨髓瘤患者,中位年龄61岁。
主要发现
- 硼替佐米或沙利度胺方案治疗的患者PFS一般长于化疗患者。
临床怎么用
- 拉丁美洲多发性骨髓瘤一线治疗趋势显示硼替佐米方案逐渐替代沙利度胺和化疗。
- 自体干细胞移植患者一线后PFS较长,非移植患者PFS较短。
- 复发患者PFS较短,尤其需关注公立诊所新疗法可及性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Limited data are available regarding contemporary multiple myeloma (MM) treatment practices in Latin America. In this retrospective cohort study, medical records were reviewed for a multinational cohort of 1103 Latin American MM patients (median age, 61 years) diagnosed in 2008-2015 who initiated first-line therapy (LOT1). Of these patients, 33·9% underwent autologous stem cell transplantation (ASCT). During follow-up, 501 (45·4%) and 129 (11·7%) patients initiated second- (LOT2) and third-line therapy (LOT3), respectively. In the LOT1 setting, from 2008 to 2015, there was a decrease in the use of thalidomide-based therapy, from 66·7% to 42·6%, and chemotherapy from, 20·2% to 5·9%, whereas use of bortezomib-based therapy or bortezomib + thalidomide increased from 10·7% to 45·5%. Bortezomib-based therapy and bortezomib + thalidomide were more commonly used in ASCT patients and in private clinics. In non-ASCT and ASCT patients, median progression-free survival (PFS) was 15·0 and 31·1 months following LOT1 and 10·9 and 9·5 months following LOT2, respectively. PFS was generally longer in patients treated with bortezomib-based or thalidomide-based therapy versus chemotherapy. These data shed light on recent trends in the management of MM in Latin America. Slower uptake of newer therapies in public clinics and poor PFS among patients with relapsed MM point to areas of unmet therapeutic need in Latin America.
引用
- de Moraes Hungria VT, Martínez-Baños DM, Peñafiel CR, et al. Multiple myeloma treatment patterns and clinical outcomes in the Latin America Haemato-Oncology (HOLA) Observational Study, 2008-2016. Br J Haematol. 2019. PMID: 31392724. doi:10.1111/bjh.16124
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。